News Briefs

Medtech startup FemTherapeutics gathers $1.85m in VC funding

2048 Ventures led the round, with participation from Investissement Quebec, The51 Ventures, Sheboot and others.

-
  • FemTherapeutics was launched to personalize pelvic medicine for women
  • The funds raised will enable FemTherapeutics to further develop its platform and devices, kick off pivotal clinical studies and expand its team, IP portfolio and research and development efforts
  • As part of the round, Alykhan Jamal, a senior manager at Becton, Dickinson and Company, was added to the board

FemTherapeutics, a Montreal-based medical technology company focused on building patient-specific gynecological prosthetics, has raised $1.85 million in financing.

2048 Ventures led the round, with participation from Investissement Quebec, The51 Ventures and Sheboot, as well as several physicians and angel investors.

Since inception, FemTherapeutics has raised a total of C$3.2 million.

As part of the round, FemTherapeutics added Alykhan Jamal, a senior manager at Becton, Dickinson and Company, to its board of directors.

FemTherapeutics was launched to personalize pelvic medicine for women. The company has developed a data and intelligence platform that leverages artificial intelligence, cloud computing, and 3D printing to produce a first category of patient-specific gynecological prosthetics. While FemTherapeutics’ first product is indicated to manage the symptoms of pelvic floor disorders, it can later be extended to key areas like maternal health, oncology, menstrual and sexual wellness.

The funds raised will enable FemTherapeutics to further develop its platform and devices, kick off pivotal clinical studies and expand its team, IP portfolio and research and development efforts.

“Medicine is moving towards a much more personalized approach, including drug delivery, diagnostics, and – as FemTherapeutics envisions – through prosthetics,” said Neha Khera, a general partner at 2048 Ventures, in a statement. “Given nearly 50% of women suffer from pelvic organ prolapse during their lifetime, we are excited by the impact FemTherapeutics can have on advancing women’s health.”